Rapid and simultaneous analysis of oral antidiabetic drug by ultra-high-speed HPLC

Yoshihiro Emoto, Ken Ishikawa, Hajime Ito, Sonoe Hiraide, Yoshiko Itoh, Hideko Kanazawa

Research output: Contribution to journalArticle

Abstract

Diabetes is a major cause of chronic kidney disease, and oral antidiabetic drugs are the mainstay of therapy for most patients with Type 2 diabetes. Type 2 diabetes is typically associated with insulin resistance and the dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together a DPP-4 inhibitor with the pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity. Ultra-high-speed HPLC has become increasingly popular in analytical research fields. This novel analytical system provides fast and efficient chromatographic separation over a wide range of flow rate and pressure. In this study, we investigated the analysis of active ingredients in combination drugs using an ultra-high-speed HPLC system equipped with a photo-diode array detector. The HPLC system utilized in this study was a LaChrom Ultra system (Hitachi, Tokyo, Japan), equipped with a L-2455U diode array detector. A LaChrom Ultra C18 (particle size; 2 μm) was used as the analytical column. Rapid and simultaneous analysis of active ingredients in combination drugs was achieved.

Original languageEnglish
Pages (from-to)725-730
Number of pages6
JournalBunseki Kagaku
Volume62
Issue number8
DOIs
Publication statusPublished - 2013

Fingerprint

Hypoglycemic Agents
Medical problems
Insulin
pioglitazone
Drug Combinations
Diodes
Detectors
Tablets
Particle size
Flow rate
Defects

Keywords

  • Combination drugs
  • DPP-4 inhibitor
  • Oral antidiabetic drugs
  • Ultra-high-speed HPLC

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Rapid and simultaneous analysis of oral antidiabetic drug by ultra-high-speed HPLC. / Emoto, Yoshihiro; Ishikawa, Ken; Ito, Hajime; Hiraide, Sonoe; Itoh, Yoshiko; Kanazawa, Hideko.

In: Bunseki Kagaku, Vol. 62, No. 8, 2013, p. 725-730.

Research output: Contribution to journalArticle

Emoto, Yoshihiro ; Ishikawa, Ken ; Ito, Hajime ; Hiraide, Sonoe ; Itoh, Yoshiko ; Kanazawa, Hideko. / Rapid and simultaneous analysis of oral antidiabetic drug by ultra-high-speed HPLC. In: Bunseki Kagaku. 2013 ; Vol. 62, No. 8. pp. 725-730.
@article{c613fb6d92c64e7399139b1ba00d971f,
title = "Rapid and simultaneous analysis of oral antidiabetic drug by ultra-high-speed HPLC",
abstract = "Diabetes is a major cause of chronic kidney disease, and oral antidiabetic drugs are the mainstay of therapy for most patients with Type 2 diabetes. Type 2 diabetes is typically associated with insulin resistance and the dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together a DPP-4 inhibitor with the pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity. Ultra-high-speed HPLC has become increasingly popular in analytical research fields. This novel analytical system provides fast and efficient chromatographic separation over a wide range of flow rate and pressure. In this study, we investigated the analysis of active ingredients in combination drugs using an ultra-high-speed HPLC system equipped with a photo-diode array detector. The HPLC system utilized in this study was a LaChrom Ultra system (Hitachi, Tokyo, Japan), equipped with a L-2455U diode array detector. A LaChrom Ultra C18 (particle size; 2 μm) was used as the analytical column. Rapid and simultaneous analysis of active ingredients in combination drugs was achieved.",
keywords = "Combination drugs, DPP-4 inhibitor, Oral antidiabetic drugs, Ultra-high-speed HPLC",
author = "Yoshihiro Emoto and Ken Ishikawa and Hajime Ito and Sonoe Hiraide and Yoshiko Itoh and Hideko Kanazawa",
year = "2013",
doi = "10.2116/bunsekikagaku.62.725",
language = "English",
volume = "62",
pages = "725--730",
journal = "Bunseki Kagaku",
issn = "0525-1931",
publisher = "Japan Society for Analytical Chemistry",
number = "8",

}

TY - JOUR

T1 - Rapid and simultaneous analysis of oral antidiabetic drug by ultra-high-speed HPLC

AU - Emoto, Yoshihiro

AU - Ishikawa, Ken

AU - Ito, Hajime

AU - Hiraide, Sonoe

AU - Itoh, Yoshiko

AU - Kanazawa, Hideko

PY - 2013

Y1 - 2013

N2 - Diabetes is a major cause of chronic kidney disease, and oral antidiabetic drugs are the mainstay of therapy for most patients with Type 2 diabetes. Type 2 diabetes is typically associated with insulin resistance and the dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together a DPP-4 inhibitor with the pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity. Ultra-high-speed HPLC has become increasingly popular in analytical research fields. This novel analytical system provides fast and efficient chromatographic separation over a wide range of flow rate and pressure. In this study, we investigated the analysis of active ingredients in combination drugs using an ultra-high-speed HPLC system equipped with a photo-diode array detector. The HPLC system utilized in this study was a LaChrom Ultra system (Hitachi, Tokyo, Japan), equipped with a L-2455U diode array detector. A LaChrom Ultra C18 (particle size; 2 μm) was used as the analytical column. Rapid and simultaneous analysis of active ingredients in combination drugs was achieved.

AB - Diabetes is a major cause of chronic kidney disease, and oral antidiabetic drugs are the mainstay of therapy for most patients with Type 2 diabetes. Type 2 diabetes is typically associated with insulin resistance and the dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together a DPP-4 inhibitor with the pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity. Ultra-high-speed HPLC has become increasingly popular in analytical research fields. This novel analytical system provides fast and efficient chromatographic separation over a wide range of flow rate and pressure. In this study, we investigated the analysis of active ingredients in combination drugs using an ultra-high-speed HPLC system equipped with a photo-diode array detector. The HPLC system utilized in this study was a LaChrom Ultra system (Hitachi, Tokyo, Japan), equipped with a L-2455U diode array detector. A LaChrom Ultra C18 (particle size; 2 μm) was used as the analytical column. Rapid and simultaneous analysis of active ingredients in combination drugs was achieved.

KW - Combination drugs

KW - DPP-4 inhibitor

KW - Oral antidiabetic drugs

KW - Ultra-high-speed HPLC

UR - http://www.scopus.com/inward/record.url?scp=84940327622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940327622&partnerID=8YFLogxK

U2 - 10.2116/bunsekikagaku.62.725

DO - 10.2116/bunsekikagaku.62.725

M3 - Article

VL - 62

SP - 725

EP - 730

JO - Bunseki Kagaku

JF - Bunseki Kagaku

SN - 0525-1931

IS - 8

ER -